EmitBio Demonstrates Statistically Significant Results in Clinical Trial for COVID-19 Treatment

Investigational treatment reduces viral load leading to meaningful patient outcomes

Durham, N.C. (February 17, 2021) – EmitBio Inc., today announced statistically significant efficacy results from its randomized, placebo-controlled, double-blind Phase I/II clinical trial. The study was conducted with an investigational treatment device* that directs precise wavelengths of safe, visible light targeted to the back of the throat and surrounding tissues. The device is designed for self-treatment of COVID-19 in an at-home setting. EmitBio™ achieved clinically and statistically significant results in both the reduction of SARS-CoV-2 viral load and accelerated time to symptom resolution in adults with COVID-19.